Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
Materials and methods. In this paper, we review publications on the significance of interleukin-(IL)-23 in the pathogenesis of plaque psoriasis and analyse the results of the 1st and 2nd phase clinical studies, as well as the 3rd phase comparative studies VOYAGE 1, VOYAGE 2, NAVIGATE and ECLIPSE on...
Saved in:
Main Author: | V. V. Chikin (Author) |
---|---|
Format: | Book |
Published: |
State Scientific Center of Dermatovenereology and Cosmetology,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024) -
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021) -
Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022) -
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
by: Melinda Gooderham, et al.
Published: (2024) -
Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)